Comments on “Serological response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 prime-boost vaccination”

Comments on “Serological response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 prime-boost vaccination”

Bibliographic Details
Main Authors:	Rujittika Mungmunpuntipantip, Viroj Wiwanitkit
Format:	Article
Language:	English
Published:	Elsevier 2023-01-01
Series:	Journal of the Formosan Medical Association
Online Access:	http://www.sciencedirect.com/science/article/pii/S0929664622003266

Similar Items

Response to comments on “Serological response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 prime-boost vaccination”
by: Wang-Huei Sheng, et al.
Published: (2023-01-01)

Humoral immune response to an mRNA-1273 booster after chAdOx1-nCoV-19-priming among patients undergoing hemodialysis
by: Bo-Yu Cheng, et al.
Published: (2023-01-01)

Evaluation of Antibody Response to Heterologous Prime–Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2: An Observational Study
by: Davide Firinu, et al.
Published: (2021-12-01)

Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19
by: Chiara Agrati, et al.
Published: (2021-11-01)

Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines
by: Guy Cohen, et al.
Published: (2022-11-01)

Humoral Immunogenicity of mRNA Booster Vaccination after Heterologous CoronaVac-ChAdOx1 nCoV-19 or Homologous ChAdOx1 nCoV-19 Vaccination in Patients with Autoimmune Rheumatic Diseases: A Preliminary Report
by: Porntip Intapiboon, et al.
Published: (2023-02-01)

Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers
by: Louise Benning, et al.
Published: (2021-08-01)

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study
by: Kriangkrai Tawinprai, et al.
Published: (2023-01-01)

Safety and immunogenicity of CoronaVac and ChAdOx1 heterologous prime-boost vaccines in an overweight population in Chiang Mai, Thailand
by: Kriangkrai Chawansuntati, et al.
Published: (2024-06-01)

Immunogenicity and Safety of Homologous and Heterologous Prime-Boost of CoronaVac<sup>®</sup> and ChAdOx1 nCoV-19 among Hemodialysis Patients: An Observational Prospective Cohort Study
by: Phoom Narongkiatikhun, et al.
Published: (2023-03-01)

Lung Transplant Recipients Immunogenicity after Heterologous ChAdOx1 nCoV-19—BNT162b2 mRNA Vaccination
by: Emilie Catry, et al.
Published: (2022-07-01)

Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population
by: Nawamin Pinpathomrat, et al.
Published: (2022-05-01)

An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines
by: Alexandre Vallée, et al.
Published: (2021-08-01)

Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study
by: Niko Kohmer, et al.
Published: (2023-03-01)

Comparison of Humoral Antibody Responses and Seroconversion Rates between Two Homologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination in Patients Undergoing Maintenance Hemodialysis
by: Shih-Hsin Hsiao, et al.
Published: (2023-06-01)

Durability of ChAdOx1 nCov-19 vaccination in people living with HIV
by: Ogbe, A, et al.
Published: (2022)

Process- and product-related impurities in the ChAdOx1 nCov-19 vaccine
by: Lea Krutzke, et al.
Published: (2022-07-01)

LGI-1 encephalopathy following ChAdOx1 nCov-19 vaccination
by: Tamara Garibashvili, et al.
Published: (2022-06-01)

Durability of Humoral and Cellular Immunity after an Extended Primary Series with Heterologous Inactivated SARS-CoV-2 Prime-Boost and ChAdOx1 nCoV-19 in Dialysis Patients (ICON3)
by: Sarinya Boongird, et al.
Published: (2022-07-01)

Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals.
by: Sana Eybpoosh, et al.
Published: (2023-11-01)

Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals
by: Sana Eybpoosh, et al.
Published: (2023-11-01)

Author Correction: Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population
by: Nawamin Pinpathomrat, et al.
Published: (2022-09-01)

Humoral Response Induced by Prime-Boost Vaccination with the ChAdOx1 nCoV-19 and mRNA BNT162b2 Vaccines in a Teriflunomide-Treated Multiple Sclerosis Patient
by: Yves Michiels, et al.
Published: (2021-10-01)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
by: Hermosilla, E, et al.
Published: (2022)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
by: Eduardo Hermosilla, et al.
Published: (2022-03-01)

DIC-Like Syndrome Following Administration of ChAdOx1 nCov-19 Vaccination
by: Gerardo Casucci, et al.
Published: (2021-06-01)

AZD1222 (ChAdOx1 nCoV-19) Vaccine: Hurdles and Visions
by: Md. Altamash Ahmad, et al.
Published: (2023-03-01)

Serological Immune Response Following ChAdOx1 nCoV-19 Vaccine (Covishield<sup>®</sup>) in Patients with Liver Cirrhosis
by: Amit Goel, et al.
Published: (2022-10-01)

Fulminant Giant Cell Myocarditis following Heterologous Vaccination of ChAdOx1 nCoV-19 and Pfizer-BioNTech COVID-19
by: Dong-Hoon Kang, et al.
Published: (2022-03-01)

Breakthrough infections and waning immune responses with ChAdOx1 nCoV‐19 or mRNA vaccine in healthcare workers
by: So Yun Lim, et al.
Published: (2022-04-01)

Myocarditis and COVID-19 mRNA vaccination
by: Rujittika Mungmunpuntipantip, et al.
Published: (2022-08-01)

ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates - author's reply
by: Voysey, M, et al.
Published: (2021)

Chronic Inflammatory Demyelinating Polyneuropathy after ChAdOx1 nCoV-19 Vaccination
by: Caterina Francesca Bagella, et al.
Published: (2021-12-01)

Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan
by: Jer-Hwa Chang, et al.
Published: (2022-02-01)

Effectiveness of the chAdOx1 nCoV-19 vaccine in preventing COVID-19 infection
by: Tarana Sarwat, et al.
Published: (2022-01-01)

An autopsy case of cerebral arterial thrombosis after vaccination with ChAdOx1 nCOV-19
by: Hyeji Yang, et al.
Published: (2022-08-01)

Myocardial infarction after ChAdOx1 nCoV-19 in a young male
by: V V. S. S. Sagar, et al.
Published: (2022-01-01)

Erythrodermic psoriasis following ChAdOx1 nCOV-19 vaccination: A case report
by: Pei-Tzu Lin, et al.
Published: (2022-01-01)

Delayed skin reactions and mRNA vaccines against SARS-CoV-2
by: Rujittika Mungmunpuntipantip, et al.
Published: (2022-10-01)

Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies
by: Mohammad Shehab, et al.
Published: (2021-12-01)